Business Model Breakdown
How Strata Skin Sciences Inc Makes Money
SSKN
Market Cap
$795,495.8
Annual Revenue
$30M
Profit Margin
-35.6%
The Short Version
Strata Skin Sciences develops, manufactures, and markets medical devices primarily for dermatologists to treat chronic skin conditions like psoriasis, vitiligo, and acne. The company generates revenue by selling its XTRAC and Pharos excimer laser systems to clinics and dermatological practices, and through recurring revenue from associated consumables and maintenance service contracts. Essentially, they sell specialized laser equipment and the ongoing supplies/support needed to operate them.
Where the Revenue Comes From
Equipment sales (excimer laser systems)
Recurring revenue from consumables and service contracts
Who buys: Dermatologists, medical spas, and aesthetic clinics treating chronic skin conditions.
Why It Works (Competitive Advantages)
- ✔Established excimer laser technology (XTRAC, Pharos)
- ✔Recurring revenue model from service and consumables (though insufficient to achieve profitability)
Economic Moat: None
What Our Analysis Says
DVR Score as of April 30, 2026
SSKN operates in a niche dermatological market with established, non-revolutionary laser technology. The company's persistent unprofitability (Trailing P/E -0.1) and extremely tight financial position are severe red flags, now compounded by a catastrophic 96%+ decline in share price (from $3.86 to $0.1351 within 52 weeks). This dramatic value destruction, coupled with a stated market cap of $0.00B (likely a rounding error for a very low single-digit million figure), indicates severe financial distress and a company fighting for survival. There are no reported disruptive competitive advantages, major partnerships, or transformative catalysts to suggest a path to 10x growth. The firm faces high delisting risk and potential bankruptcy, making a multi-bagger return highly improbable. The score reflects a critical decline in fundamental health since the last analysis.